Drugs / VSJ-110
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07179055 | Oct 2025 → Sep 2026 overdue | dry eye syndrome | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06296966 | Feb → Jul 2024 | dry eye syndrome | Vanda Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT04622345 | Nov 2020 → May 2021 | conjunctivitis | Vanda Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-26 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator VSJ-110 (previously known as CFTR act -K267) for the treatment of allergic conjunctivitis. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-26 | Vanda Pharmaceuticals | Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis vandapharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSJ-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622345 ↗ |
| Route | Other | “ophthalmic solution” NCT04622345 ↗ |